Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Sep-Oct;29(5):e13142.
doi: 10.1111/hel.13142.

Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children-Data From the RENIHp Registry

Gonzalo Botija  1 , Gonzalo Galicia  2 , Beatriz Martínez  3 , Carmen Cuadrado  4 , Marta Soria  5 , Sonia Fernández  6 , Pedro Urruzuno  7 , María-Luz Cilleruelo  8 ; SEGHNP H. pylori Working Group
Affiliations
Multicenter Study

Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children-Data From the RENIHp Registry

Gonzalo Botija et al. Helicobacter. 2024 Sep-Oct.

Abstract

Objectives: To evaluate the efficacy of colloidal bismuth subcitrate (CBS) therapy for the eradication of H. pylori in patients from a national pediatric registry of H. pylori infection.

Methods: The Spanish Registry of Children with H. pylori Infection (RENIHp) is a national, multi-center, prospective, non-interventional registry that includes children aged 5-18 years with H. pylori infection diagnosed by endoscopy. All patients in the registry who were treated with CBS between the period 2020 and 2023 were included in this study. The primary outcome was the eradication rate, which was assessed using a 13C-urea breath test or monoclonal antigen in the stool 6-8 weeks post-treatment.

Results: The registry included 682 patients, 38 (5.6%) of whom underwent treatment with CBS. Fifty percent (19/38) of patients had previously undergone unsuccessful eradication treatment. In 78.9% (30/38) of patients, treatment was guided by an antibiotic sensitivity test. In the remaining patients, an empirical approach was employed. The CBS therapies used were as follows: quadruple therapy with proton pump inhibitors (PPIs), CBS, amoxicillin, and metronidazole (MET) [18/38 (47.3%)]; quadruple therapy with PPIs, CBS, tetracycline, and MET [13/38 (34.2%)]; and other therapies [7/38 (18.4%)]. Thirty-two patients (84.2%) treated with CBS were followed-up with eradication monitoring. The overall eradication rate in patients treated with CBS was 93.8% (30/32, [95% CI: 85.4%-100%]), whereas it was 86.7% in patients in the registry who were not on CBS treatment (430/496, [95% CI: 83.3%-89.5%], p = 0.208). In the six patients with dual resistance to clarithromycin (CLA) and MET who were treated with quadruple therapy with CBS, the eradication rate was 100% (n = 6/6, [95% CI: 61.0%-100%]).

Conclusion: CBS therapies in our registry, although only used in selected cases and at lower than recommended levels, were very effective and showed an eradication rate of > 90%.

Keywords: Helicobacter pylori; bismuth; eradication therapy; pediatric.

PubMed Disclaimer

References

    1. N. L. Jones, S. Koletzko, K. Goodman, et al., “Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016),” Journal of Pediatric Gastroenterology and Nutrition 64, no. 6 (2017): 991–1003.
    1. H. Alkim, A. R. Koksal, S. Boga, I. Sen, and C. Alkim, “Role of Bismuth in the Eradication of Helicobacter pylori,” American Journal of Therapeutics 24, no. 6 (2017): e751–e757.
    1. J. D. S. Rosário, F. H. Moreira, L. H. F. Rosa, et al., “Biological Activities of Bismuth Compounds: An Overview of the New Findings and the Old Challenges Not Yet Overcome,” Molecules 28, no. 15 (2023): 5921.
    1. R. Ge, Z. Chen, and Q. Zhou, “The Actions of Bismuth in the Treatment of Helicobacter pylori Infections: An Update,” Metallomics 4 (2012): 239–243.
    1. E. A. Marcus, G. Sachs, and D. R. Scott, “Colloidal Bismuth Subcitrate Impedes Proton Entry Into Helicobacter pylori and Increases the Efficacy of Growth‐Dependent Antibiotics,” Alimentary Pharmacology & Therapeutics 42, no. 7 (2015): 922–933.

Publication types

MeSH terms

LinkOut - more resources